Free Trial

MoonLake Immunotherapeutics Q2 2023 Earnings Report

MoonLake Immunotherapeutics logo
$37.21 -0.85 (-2.23%)
As of 04:00 PM Eastern

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q2 2023
Time
Before Market Opens
Remove Ads

MoonLake Immunotherapeutics Earnings Headlines

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile

More Earnings Resources from MarketBeat